PF 6649751

Drug Profile

PF 6649751

Alternative Names: PF-06649751; PF-6649751

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Dopamine D1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 22 Nov 2017 Pfizer terminates phase II trial in Parkinson's disease in USA, France, Germany, Spain and Japan (NCT02687542)
  • 24 Oct 2017 Pfizer terminates a phase II trial in Parkinson's disease (Treatment-experienced) in USA, Spain, Germany due to insufficient efficacy observed in parent study (PO) (NCT03185481) (EudraCT2017-000128-81)
  • 14 Sep 2017 Pfizer completes a phase I trial in Healthy volunteers in Belgium (NCT03121664)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top